health 49

Principal results were published in the  New England Journal of Medicine  of a global Phase 3 clinical trial in patients with type 1 diabetes treated with sotagliflozin. Sotagliflozin is an investigational new oral drug for patients with type 1 diabetes that has shown promise in improving glucose control without any increase in severe hypoglycemia or diabetic ketoacidosis compared to insulin alone. Among 1,402 trial participants given the drug, sotagliflozin showed clinically meaningful and statistically significant effects on glucose control. Concentrations of hemoglobin A1C, a measure of plasma glucose, were improved. Patients experienced a lower rate of confirmed severe hypoglycemia than observed in patients on placebo and also had weight loss. According to lead investigator Satish Garg, MD, professor of medicine and pediatrics at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus, no oral medication has ever been approved for...

"Ecstasy or 'Molly' users in the U.S. are at very high risk for using drugs containing adulterants such as 'bath salts' and methamphetamine," said Dr. Joseph Palamar, PhD, MPH, of the New York University Rory Meyers College of Nursing Center for Drug Use and HIV Research (NYU CDUHR). "More information is critically needed on the extent of unknown or unintentional use of these potentially harmful substances." Dr. Palamar's study, "Hair Testing to Assess Both Known and Unknown Use of Drugs Amongst Ecstasy Users in the Electronic Music Dance Scene," published in the  International Journal of Drug Policy , surveyed self-reported past-year ecstasy/MDMA/Molly users attending EDM parties in New York City (NYC), using hair testing to determine the types of drugs participants had consumed. "Hair testing for new psychoactive substances is an important new addition to biological testing. While blood, urine, and saliva are often adequate...

The study, which is one of the largest on glioblastoma treatment and outcomes, also shows that patients treated at high-volume centers live approximately three and one-half months longer than patients treated at low-volume centers. Dr. Matthew Koshy, corresponding author on the paper, says this difference in outcomes is on par with results seen in phase III clinical trials -- the last of which for glioblastoma was two years ago. "It has been very difficult to find new treatments for glioblastoma, and there has been little progress toward improving outcomes for patients suffering from this type of cancer," said Koshy, radiation oncologist at the University of Illinois Hospital & Health Sciences System. "To see a significant difference in outcomes, based solely on type of facility, offers strong and, more importantly, actionable evidence that physicians and patients can use today as they consider treatment options." While the researchers say it is not surp...

The study was published last month in an online edition of  Psychiatry Research . Individuals who have had mild or transient psychotic symptoms (such as unusual thoughts, suspiciousness, perceptual disturbances) without using substances such as marijuana or alcohol and have a family history of psychosis or other risk factors are considered at clinical high risk for psychotic disorder. Previous studies have found an association between marijuana use and psychosis in the general population, but none have rigorously examined marijuana's effects in those at greatest risk for psychosis. "Many adolescents and young adults who are at high risk for psychosis smoke marijuana regularly or have a cannabis use disorder," said Margaret Haney, PhD, professor of neurobiology (in Psychiatry) at CUMC and senior author of the paper. "Yet researchers haven't studied the effects of marijuana in this population in a rigorous, controlled manner." In this double-blinded, p...